

Contact: Hariharan Subramanian
PancreaSolve, Inc.
Phone: (617) 553-1015
701 Concord Avenue
Cambridge, MA 02138
info@pancreasolve.com
www.pancreasolve.com

PancreaSolve™

PRESS RELEASE

PancreaSolve, Inc. gets exclusive license of CytoSolve's in silico models of pancreatic cancer

Cambridge, November 1, 2015: In a milestone agreement, PancreaSolve, Inc. obtained exclusive licensing agreement for the in silico models from CytoSolve, Inc. These models will be used to accelerate the development of therapeutics for pancreatic cancer.

"We are excited to have this agreement in place as it enables us to use CytoSolve's in silico models of pancreatic cancer for discovering new combination drugs for pancreatic cancer which then can be tested at MD Anderson cancer in the in vitro and in vivo settings," said Dr. Shiva Ayyadurai, Chief Executive Officer of PancreaSolve.

PancreaSolve is headquartered in Cambridge, MA. PancreaSolve uses CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics.

CytoSolve is headquartered in Cambridge, MA. CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics.

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is a premier cancer center in the world, based on the excellence in research-driven patient care and cutting-edge science.